Effectiveness and Safety of Oral Chinese Patent Medicines Combined with Chemotherapy for Gastric Cancer: A Bayesian Network Meta-Analysis

Table 1

The basic characteristics of the included studies.

Study ID	TNM stages	Sample size (E/C)	Sex, M/F	Age (E/C)	Intervention		Course (d × c)	Outcomes
					E	C
Hong et al. [13]	III∼IV	60/60	79/41	58.0/56.5	ATK 0.44 g, tid + SOX	SOX	≥21d  ×  2	①②
Qian and Zuo [14]	III∼IV	40/40	59/21	62.5(19∼74)/62(38∼77)	BZ 3.5 g, bid + 5-Fu + THP + L-OHP	5-Fu + THP + L-OHP	21 d  ×  3	①③④
Zhu et al. [15]	III∼IV	27/27	36/18	61(19∼73)/58(24∼75)	SQSYW 2g, tid + EOX	EOX	≥21 d  ×  2	①②③④
Guo et al. [16]	III∼IV	42/38	40/40	66.4 ± 4.2/64.8 ± 3.7	HCS 0.9 g,qid + FOLFOX6	FOLFOX6	21 d  ×  6	①
Zha and Hang [17]	III∼IV	20/20	24/16	50∼72	HCS 0.5 g,tid + oxaliplatin 130 mg/m^2 + Tegafur 600 mg/m^2 + CF 200 mg/m^2	Oxaliplatin 130 mg/m^2 + Tegafur 600 mg/m^2 + CF 200 mg/m^2	21 d  ×  6	①③④
Lu et al. [18]	III∼IV	30/30	23/37	73.7 ± 5.1/74.8 ± 6.2	HCS 0.5 g, tid + capecitabine 1250 mg/m^2	Capecitabine 1250 mg/m^2	≥21 d  ×  2	①②③④
Ren [19]	III∼IV	47/47	54/40	51.24 ± 3.98/50.15 ± 3.87	HCS 0.5 g, tid + SOX	SOX	21 d  ×  2	①②④
Wu et al. [20]	IV	25/25	27/23	59.14 ± 4.37/58.57 ± 4.23	HCS 0.5 g, tid + XELOX	XELOX	21 d  ×  2	①④
Yan et al. [21]	IIIB∼IV	35/35	38/32	49.5 ± 6.4/48.76 ± 6.5	HCS 0.9 g, tid + oxaliplatin 85 mg/m^2 + capecitabine 1000 mg/m^2	Oxaliplatin 85 mg/m^2 + capecitabine 1000 mg/m^2	21 d  ×  6	①②③④
Ling [22]	III∼IV	48/48	61/35	54.27 ± 7.92/55.03 ± 7.51	HCS 0.9 g, tid + FOLFOX4	FOLFOX4	14 d  ×  3	①②③④
Xu and Liu [23]	III∼IV	30/30	32/28	45. 8(36∼70)/49. 9(37∼70)	HCS 0.9 g, tid + L-OHP 130 mg/m^2 + 5-FU 300 mg/m^2 + CF 200 mg/m^2	L-OHP 130 mg/m^2 + 5-FU 300 mg/m^2 + CF 200 mg/m^2	≥21 d  ×  2	①③④
Yang and Zhang [24]	IV	25/25	35/15	54(31∼75)/50(37∼70)	HCS 0.5 g,tid + EOF	EOF	≥21 d  ×  2	①②③④
Li et al. [25]	III∼IV	30/30	38/22	61.5 ± 9.0/60.8 ± 8.8	HCS 0.9 g, tid + SOX	SOX	21 d   × 2	①④
Cao [26]	NR	41/41	44/38	54.8 ± 5.4/56.3 ± 4.6	HCS 0.9 g, tid + S-1 60 mg/m^2	S-1 60 mg/m^2	28 d  ×  2	①②
Wang and et al. [27]	NR	58/58	59/57	58. 4/58. 8	HCS 0.5 g, tid + S-1 80 mg/m^2	S-1 80 mg/m^2	21 d  ×  2	①②④
Chen et al. [28]	I∼IV	33/33	36/30	48.8	PX 1.15∼1.84 g, tid + ELF	ELF	21 d  ×  2	①②④
Que and Wang [29]	NR	44/43	49/38	52(35∼69)	PX 1.38 g, tid + DDP + 5-Fu	DDP + 5-Fu	21 d  ×  2	①④
Fan et al. [30]	III∼IV	47/46	55/38	52(32∼69)	PX 1.25 g, bid + DDP + 5-Fu	DDP + 5-Fu	21 d  ×  1	①
Ning and Hao [31]	II∼IV	121/49	126/44	54.3/56.1	PX 1.68 g, tid + mFAM	mFAM	≥21 d  ×  3	①
Chen et al. [32]	III∼IV	30/28	43/15	51(32∼69)/50(29∼68)	PX 1.38 g,tid + ECF	ECF	21 d  ×  2	①③④
Gu [33]	IV	50/50	61/39	45.81 ± 8.79/45.17 ± 8.92	PX 1.15 g, tid + DCF	DCF	21 d  ×  4	①④
Zhang et al. [34]	III∼IV	46/46	61/31	54.3 ± 6.8/52.6 ± 6.3	XAP 3 g, bid + PF	PF	28 d  ×  2	①②③④
Huang and Guo [35]	NR	36/36	41/31	61.42 ± 11.20	XAP 2.4 g, tid + FOLFOX4/XELOX/EOF	FOLFOX4/XELOX/EOF	NR	③④
Wang [36]	NR	150/150	166/134	62.34 ± 8.37/63.16 ± 8.84	XAP 1.8∼2.4 g, tid + SOX	SOX	21 d  ×  4	①
Li [37]	IV	32/30	37/25	62.2 ± 3.4/63.6 ± 3.2	XAP + chemotherapy	Chemotherapy	NR	①④
Shi [38]	NR	53/53	56/50	56.28 ± 4.82	XAP 2.04∼2.55 g, tid + EOF/OLF	EOF/OLF	NR	③④
Liu [39]	III	46/46	57/35	57.2 ± 4.1/56.1 ± 3.5	ZQFZ 15 g, bid + FOLFOX4	FOLFOX4	≥14 d × 2	①③④
Wei [40]	NR	30/30	34/26	43∼72/46∼75	ZQFZ 5g, bid + 5-Fu + L-OHP + CF + MMC	5-Fu + L-OHP + CF + MMC	28d × 1	②
Hu et al. [41]	II∼IV	40/40	46/34	54.3 ± 10.3/52.5 ± 11.1	ZQFZ 5g, tid + MLF	MLF	28 d  ×  1	②
Li and Zhang [42]	IV	26/26	34/18	65∼73	ZQFZ 5g, bid + S-1	S-1	42 d  ×  2	①③④

E, experimental group; C, control group; M, male; F, female; NR, no reported; d, day; c, cycle; ATK, Antike capsule; BZ, Bazhen granule; SQSYW, Shenqi Shiyiwei granule; HCS, Cinobufacin capsule; PX, Pingxiao capsule; XAP, Xiao’aiping tablet; ZQFZ, Zhenqi Fuzheng granule; ①, objective response rate; ②, performance status; ③, leucopenia; ④, gastrointestinal reaction.